Category: Markets
Published: 2026-07-16T13:10:47.000Z
Medtronic has completed its $650 million acquisition of SPR Therapeutics, a privately held medical technology company specializing in short-term peripheral nerve stimulation therapies for pain management. This acquisition strengthens Medtronic's position in the healthcare equipment industry and adds the FDA-cleared SPRINT PNS System to its portfolio, offering a minimally invasive, non-opioid, and non-surgical option for chronic and acute pain. The deal is expected to be minimally dilutive to Medtronic’s adjusted EPS in fiscal year 2027 and neutral to accretive thereafter.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.